All companies
Visit website
Oncolyze
OperatingONCOLYZE
Healthcare · Biotech
Biotech company aiming to treat cancer by exploding cancer cells
Latest valuation
—
No round has disclosed a priced valuation or cap.
Total raised
$2,468,969
Across 2 rounds since 2022
Latest share price
$3.524
Reg A Offering (2022) offering price
Financials
FY2021 · from SEC filings · hover any figure for its source$0
−$741K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021 audited
Income statement
Revenue
$0
Cost of goods sold
$737,574
Net income
-$740,574
Balance sheet
Cash
$179,244
Accounts receivable
$0
Total assets
$272,780
Long-term debt
$0
Total liabilities
$1,825,924
Other
Headcount
4
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Fundraising history
Raised $1.1MInvestors 738
Raised $1.3M / $15.3MInvestors 601
SEC filings
View all 14 filings on EDGARSource: ManualCIK 0001917375Share price $3.524
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.